Navigation Links
New Data Showed ACTOS(R) (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes
Date:3/31/2008

Data expands body of evidence in high risk population using IVUS, a unique

marker for coronary atherosclerosis

CHICAGO, March 31 /PRNewswire/ -- New data from a clinical trial using intravascular ultrasound (IVUS) technology found that in patients living with type 2 diabetes, ACTOS(R) (pioglitazone HCl) reduced the atherosclerotic burden in the coronary arteries compared to glimepiride, and prevented progression compared to baseline. These data stem from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) trial.

The PERISCOPE trial was presented today as a late breaker at the 57th Annual Scientific Session of the American College of Cardiology in Chicago. This trial adds to the body of cardiovascular data for ACTOS. ACTOS studies, conducted over the past 10 years in more than 16,000 patients, including short- and long-term trials, as well as prospective and observational studies, have shown no evidence that ACTOS is associated with an increased risk of heart attack, stroke, or death.

"We are pleased with the results of the PERISCOPE, which further expands our cardiovascular data with ACTOS," said David P. Recker, M.D., senior vice president, Clinical Sciences and interim president at Takeda Global Research & Development. "While not definitive, data from PERISCOPE combined with results from a previous study, looking at surrogate endpoints, have shown a consistent trend toward decreasing cardiovascular risk by reducing the atherosclerotic burden in people with type 2 diabetes."

PERISCOPE is the first clinical trial to examine the effects of an oral antidiabetic medication on the development of coronary atherosclerosis in patients with type 2 diabetes using IVUS technology. The trial conducted in 97 centers in the U.S., Canada and Latin America with 543 patients, used IVUS imaging of the coronary arteries. The analysis demonstrated a statisticall
'/>"/>

SOURCE Takeda Global Research & Development Center, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients
2. New Study of Concerta(R) Showed Significant Improvement of ADHD Symptom Management in Adults Compared to Placebo
3. One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
4. One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
5. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
6. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
7. Early Research Suggests Umbilical Cord Blood Cell Therapy May Reduce Progression of Alzheimers Disease
8. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
9. Update on Progression of Phosphagenics and Nestle Nutritions Phospha E(R) Trial
10. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
11. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 On Thursday, July ... the Dow Jones Industrial Average finished the day 0.42% lower ... 0.41%. The losses were broad based as eight out of ... Health Care Sector Index ended the day at 711.88, down ... one month. Investor-Edge has initiated coverage on the following equities: ...
(Date:7/11/2014)... 11, 2014 Show ... & Health Expo 2014 were a brand ... London , plus a ...          (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ... )      (Photo: http://photos.prnewswire.com/prnh/20140711/696892-b ...
(Date:7/10/2014)... CLEVELAND , July 10, 2014  The U.S. ... a three-year grant to University Hospitals (UH) Case Medical ... a new national model aimed at improving care for ... Oncology Care," the project will test a unique model ... patients with late-stage disease, significant comorbidities, or demonstrated need ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
... National Institute of,Standards and Technology (NIST) has selected ... Commerce Department,s Advanced Technology Program,(ATP), a peer-reviewed competition. ... the early-phase Michigan biotechnology company developing,drug therapies to ... disorders. Velcura scientists have discovered a family ...
... YORK, Sept. 27 Immtech Pharmaceuticals,Inc. (Immtech) (Amex: ... Food and Drug,Administration of the People,s Republic of ... for conducting a Phase III clinical,trial with pafuramidine, ... Pneumocystis pneumonia (PCP). Pafuramidine is among the first,drugs ...
Cached Medicine Technology:NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease 2Chinese SFDA Grants Immtech Fast Track Status 2Chinese SFDA Grants Immtech Fast Track Status 3
(Date:7/11/2014)... Obese and overweight firefighters are not receiving ... according to new research from The University of ... National guidelines state that health care professionals (HCPs) ... a healthy weight. Firefighters have high rates of ... of line-of-duty deaths in firefighters. This study assessed ...
(Date:7/11/2014)... The Corn Farming industry ... on the heels of fresh biofuel demand. The Federal ... a larger share of their farmland to cultivating high-value ... required the mixing of 5.0% renewable content in gasoline ... United States created a key export market for Canadian ...
(Date:7/11/2014)... Reinberg HealthDay Reporter THURSDAY, ... protect children from the worldwide scourge of dengue fever was ... the vaccine only prevented dengue fever in 56 percent of ... shots, it protected more than 88 percent of them from ... to hospitalization, and sometimes death. "This vaccine has already ...
(Date:7/11/2014)... Ticket Down is a reliable source for cheap ... CA. Over the years Luke Bryan has been honored by ... he do well at award shows, but each summer, he hits ... tours of the genre and this summer is more of the ... to the popularity and success that is currently entitled to Luke ...
(Date:7/11/2014)... Riverside Health System became the first provider ... in late 2012 and now, in partnership with Williamsburg Landing, ... the Williamsburg and Newport News region. , Also known as ... to independent older adults who wish to remain in their ... of continuing care services as well as control over the ...
Breaking Medicine News(10 mins):Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 2Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 3Health News:Dengue Fever Vaccine Shows Some Promise in Trial 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 3Health News:Luke Bryan Tickets Shoreline Amphitheatre in Mountain View, CA: Ticket Down Slashes Ticket Prices for Luke Bryan in Mountain View at the Shoreline Amphitheatre 2Health News:Luke Bryan Tickets Shoreline Amphitheatre in Mountain View, CA: Ticket Down Slashes Ticket Prices for Luke Bryan in Mountain View at the Shoreline Amphitheatre 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 4
... not quintessentially masculine, women in their fertile phase are ... women paired with George Clooney types. But women ... to their partners, a recent study co-authored by a ... a man,s intelligence has no effect on the extent ...
... Residents of Cuyahoga County, and later Lorain County, will ... of a national resource for childhood growth and development. ... of children,s health ever conducted in the United States. ... The study will enroll women who are pregnant ...
... -- People over age 65 are at increased risk for ... study finds. Latent tuberculosis occurs when TB bacteria lurk ... has no symptoms of TB and is not contagious. However, ... cause tuberculosis, which can be fatal if it goes untreated. ...
... has received a boost from a surprising source: the 2009 ... 2009 H1N1 strain developed antibodies that are protective against a ... Medicine and the University of Chicago have found. The results ... Medicine . "Our data shows that infection with the ...
... one of today,s most exciting scientific and clinical areas. ... rulings by regulatory bodies or ethical controversies. These often ... ethicists, legislators, the media and the public. ESHRE,s ... of the world,s leading experts in reproductive medicine gather ...
... Race and ethnicity play major roles in whether people get ... much less likely to undergo colonoscopies than white people. Now, ... people live. Research by oncologist Dr. Thomas Semrad ... Center found that location makes a big difference in rates ...
Cached Medicine News:Health News:Men with macho faces attractive to fertile women, researchers find 2Health News:Men with macho faces attractive to fertile women, researchers find 3Health News:Case Western Reserve University School of Medicine launches the National Children's Study 2Health News:Treating Latent TB After 65 Raises Serious Side-Effect Risk 2Health News:Pandemic flu strain could point way to universal vaccine 2Health News:Pandemic flu strain could point way to universal vaccine 3Health News:ESHRE bridges East and West for its 2012 Congress in Istanbul 2Health News:Geography May Influence Colon Cancer Screening Rates 2
... Beta 200 ophthalmoscope, ... glare-free direct ophthalmoscope. Heine's ... patent #4,963,014) along with ... construction, make the Beta ...
... optics. The separation of illumination and observation ... system avoids corneal and iris reflex (Gullstrand-principle). ... the whole of the illuminated section of ... Conventional ophthalmoscopes often let you see only ...
... Beta 200S is the first ... combination of patented aspherical optics ... range of corrective lenses from ... single diopter steps. A perfectly-focused ...
With the unique automatic focus system, Autofoc 2 remains the instrument of choice for direct ophthalmoscopy. Includes XHL halogen bulb....
Medicine Products: